A mathematical model of combination therapy using the EGFR signaling network

被引:65
作者
Araujo, RP
Petricoin, EF
Liotta, LA
机构
[1] NCI, FDA, Clin Proteom Program, Lab Pathol,Ctr Canc Res,NIH, Bethesda, MD 20892 USA
[2] US FDA, NCI, Clin Proteom Program, Off Cell & Gene Therapies,Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA
关键词
cancer treatment; combination therapy; EGFR network; signal transduction; kinase inhibitors;
D O I
10.1016/j.biosystems.2004.10.002
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
An increasing awareness of the significance of abnormal signal transduction in tumors and the concomitant development of target-based drugs to selectively modulate aberrantly-activated signaling pathways has given rise to a variety of promising new strategies in cancer treatment. This paper uses mathematical modeling to investigate a novel type of combination therapy in which multiple nodes in a signaling cascade are targeted simultaneously with selective inhibitors, pursuing the hypothesis that such an approach may induce the desired signal attenuation with lower doses of the necessary agents than when one node is targeted in isolation. A mathematical model is presented which builds upon previous theoretical work on EGFR signaling, simulating the effect of administering multiple kinase inhibitors in various combinations. The model demonstrates that attenuation of biochemical signals is significantly enhanced when multiple upstream processes are inhibited, in comparison with the inhibition of a single upstream process. Moreover, this enhanced attenuation is most pronounced in signals downstream of serially-connected target points. In addition, the inhibition of serially-connected processes appears to have a supra-additive (synergistic) effect on the attenuation of downstream signals, owing to the highly non-linear relationships between network parameters and signals. (c) 2004 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:57 / 69
页数:13
相关论文
共 17 条
  • [1] Combining EGFR inhibitors with radiation or chemotherapy: Will preclinical studies predict clinical results?
    Harari, PM
    Huang, SM
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 58 (03): : 976 - 983
  • [2] Mathematical models of protein kinase signal transduction
    Heinrich, R
    Neel, BG
    Rapoport, TA
    [J]. MOLECULAR CELL, 2002, 9 (05) : 957 - 970
  • [3] Quantification of short term signaling by the epidermal growth factor receptor
    Kholodenko, BN
    Demin, OV
    Moehren, G
    Hoek, JB
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (42) : 30169 - 30181
  • [4] KOIZUMI F, 1924, INT J CANCER, V108, P464
  • [5] Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: Focus on NSCLC
    Langer, CJ
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 58 (03): : 991 - 1002
  • [6] Clinical proteomics - Personalized molecular medicine
    Liotta, LA
    Kohn, EC
    Petricoin, EF
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (18): : 2211 - 2214
  • [7] Signaling switches and bistability arising from multisite phosphorylation in protein kinase cascades
    Markevich, NI
    Hoek, JB
    Kholodenko, BN
    [J]. JOURNAL OF CELL BIOLOGY, 2004, 164 (03) : 353 - 359
  • [8] Synergistic antiproliferative and apoptotic effects induced by epidermal growth factor receptor and protein kinase a inhibitors in human prostatic cancer cell lines
    Mimeault, M
    Pommery, N
    Hénichart, JP
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2003, 106 (01) : 116 - 124
  • [9] Protein kinase inhibitors: Insights into drug design from structure
    Noble, MEM
    Endicott, JA
    Johnson, LN
    [J]. SCIENCE, 2004, 303 (5665) : 1800 - 1805
  • [10] Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily - Role as anticancer agents
    Noonberg, SB
    Benz, CC
    [J]. DRUGS, 2000, 59 (04) : 753 - 767